Impacto diagnóstico y terapéutico de la 18F-FDG-PET/TAC en pacientes con sospecha de recidiva de cáncer de mama

Palomar Muñoz, A; García Vicente, AM; Talavera Rubio, MP; Pilkington Woll, JP; Poblete García, VM; Bellón Guardia, ME; León Martín, A; Cordero García, JM; Soriano Castrejón, A.
Rev. esp. med. nucl. (Ed. impr.) ; 29(3): 100-108, mayo-jun. 2010. tab, ilus
Artigo Espanhol | IBECS (Espanha) | ID: ibc-79408

Documentos relacionados

  1. Outcomes of solitary postoperative recurrence of esophageal squamous cell carcinoma diagnosed with FDG-PET/CT and treated with definitive radiation therapy.
  2. Impact of Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography on Therapeutic Decisions and Radiotherapy Planning in Head and Neck Squamous Carcinoma: A Retrospective Study of 46 Patients.
  3. Cardiac metabolic changes on <sup>18</sup> F-positron emission tomography after thoracic radiotherapy predict for overall survival in esophageal cancer patients.
  4. Joint EANM/SNMMI/ESTRO practice recommendations for the use of 2-[<sup>18</sup>F]FDG PET/CT external beam radiation treatment planning in lung cancer V1.0.
  5. A feasibility study on adaptive <sup>18</sup>F-FDG-PET-guided radiotherapy for recurrent and second primary head and neck cancer in the previously irradiated territory.
  6. Management and prognosis of cervical cancer patients treated with definitive radiation therapy who have partial metabolic response on post-therapy positron emission tomography.
  7. Metabolic parameters of [<sup>18</sup>F]FDG PET-CT before and after radiotherapy may predict survival and recurrence in cervical cancer.
  8. Comparative assessment of radiation therapy-induced vasculitis using [<sup>18</sup>F]FDG-PET/CT in patients with non-small cell lung cancer treated with proton versus photon radiotherapy.
  9. [F18] FDG-PET/CT for manual or semiautomated GTV delineation of the primary tumor for radiation therapy planning in patients with esophageal cancer: is it useful?
  10. Respiratory gated multistatic PET reconstructions to delineate radiotherapy target volume in patients with mobile lung tumors.